The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1567
ISSUE 1567
March 11, 2019
Issue 1567
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue. |
Drugs for Gout
March 11, 2019 (Issue: 1567)
Drugs for gout reduce the pain and inflammation of
acute flares and lower serum urate levels in order to
prevent recurrent flares, development of tophi, and
joint damage.
... more
- D Khanna et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012; 64:1431.
- D Khanna et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012; 64:1447.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2017 September 18 (epub). Available at: www. medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- CA Billy et al. Corticosteroid or nonsteroidal antiinflammatory drugs for the treatment of acute gout: A systematic review of randomized controlled trials. J Rheumatol 2018; 45:128.
- MD Wechalekar et al. Intra-articular glucocorticoids for acute gout. Cochrane Database Syst Rev 2013; 4:CD009920.
- G Bandoli et al. A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes. Rheum Dis Clin North Am 2017; 43:489.
- Canakinumab (Ilaris) for systemic juvenile idiopathic arthritis. Med Lett Drugs Ther 2013; 55:65.
- N Schlesinger et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012; 71:1839.
- P Ghosh et al. Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. Arthritis Care Res (Hoboken) 2013; 65:1381.
- TJ Major et al. Evaluation of the diet wide contribution to serum urate levels: meta-analysis of population based cohorts. BMJ 2018; 363:k3951.
- SM Nielsen et al. Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. Ann Rheum Dis 2017; 76:1870.
- T Neogi et al. Alcohol quantity and type on risk of recurrent gout attacks: an internet-based case-crossover study. Am J Med 2014; 127:311.
- AB Vargas-Santos et al. Association of chronic kidney disease with allopurinol use in gout treatment. JAMA Intern Med 2018; 178:1526.
- Febuxostat (Uloric) for chronic treatment of gout. Med Lett Drugs Ther 2009; 51:37.
- MA Becker et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010; 12:R63.
- FDA Drug Safety Communication: FDA adds boxed warning for increased risk of death with gout medicine Uloric (febuxostat). Available at: www.fda.gov. Accessed February 27, 2019.
- N Dalbeth et al. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial. Arthritis Rheumatol 2017; 69:1903.
- H Yu et al. Safety and efficacy of benzbromarone and febuxostat in hyperuricemia patients with chronic kidney disease: a prospective pilot study. Clin Exp Nephrol 2018 May 14 (epub).
- KG Saag et al. Efficacy and safety of febuxostat extended and immediate release in patients with gout and renal impairment: a phase III placebo-controlled study. Arthritis Rheumatol 2019; 71:143.
- WB White et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 2018; 378:1200.
- ME Kleber et al. Uric acid and cardiovascular events; a Mendelian randomization study. J Am Soc Nephrol 2015; 26:2831.
- HW Park et al. Efficacy of the HLA-B*58:01 screening test in preventing allopurinol-induced severe cutaneous adverse reactions in patients with chronic renal insufficiency-A prospective study. J Allergy Clin Immunol Pract 2018 Dec 21 (epub).
- I Kamilli and U Gresser. Allopurinol and oxypurinol in human breast milk. Clin Investig 1993; 71:161.
- JY Wu et al. Efficacy and safety of lesinurad in patients with hyperuricemia associated with gout: a systematic review and meta-analysis of randomized controlled trials. Pharmacotherapy 2018; 38:1106.
- KF Ilett et al. Transfer of probenecid and cephalexin into breast milk. Ann Pharmacother 2006; 40:986.
- Pegloticase (Krystexxa) for treatment of refractory gout. Med Lett Drugs Ther 2011; 53:9.
- JS Sundy et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011; 306:711.
- HS Baraf et al. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. J Clin Rheumatol 2014; 20:427.
- LH Calabrese et al. Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout. Arthritis Res Ther 2017; 19:191.
- S Takahashi et al. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 2003; 62:572.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1567
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian